Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Targacept reports positive schizophrenia drug study
TC-5619 is a highly selective alpha7 neuronal nicotinic receptor modulator, which is subject to licence by Targacept’s strategic partner AstraZeneca. In the trial, TC-5619 met the primary efficacy
TC-5619 is a highly selective alpha7 neuronal nicotinic receptor modulator, which is subject to licence by Targacept’s strategic partner AstraZeneca. In the trial, TC-5619 met the primary efficacy
The Phase 1/2 trial is an open-label study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and clinical activity of BMN 701. In the study, BMN 701 will
The new plant will include 8,000 liters of production capacity, a complete purification installation, and ample room for additional future capacity expansions. Commercial approvals for the new site
TransferCenter version 2.1 also features a fresh user interface for easier navigation, specific protocols by case type to help transfer personnel reduce errors, and aids to make data
PharmaVigilant claims that the I-Warehouse 3.0 offers immediate and ubiquitous access to study data with comparable results. I-Warehouse offers search criteria and a more streamlined selection process with
Under the licensing agreement, Cellectis can use all technology of the university related to any field. The technology has shown positive results in genome engineering and is complementary
A positive opinion by the COMP immediately precedes official designation of darinaparsin as an orphan drug by the European Commission (EC). Ziopharm expects to commence a registration-directed study
Clinical trials of Ceplene showed that it prolongs remission and prevents relapse in patients under the age 60, and it was also successful in averting additional 20% of
The model will be used to get a better understanding of the benefits of weight loss against the long-term risks of cardiovascular outcomes in patients treated with weight
The acquisition is expected to create in the UK a major primary care medical property and pharmacy group with property assets of £504m. Assura has also entered into